CD274 and nonpapillary renal cell carcinoma: Our study shows that exposure of tumor cells to increasing concentrations of nivolumab seems to downregulate the PD-1 expression and partially downregulate PD-L1 in ccRCC, but seems to increase PD-1 expression in pRCC.